- CEO
- He Huang
- Full Time Employees
- 3,908
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Beijing China
- IPO Date
- Jun 30, 2022
- Business
- Beijing Foyou Pharma Co., Ltd., a subsidiary of NHU Holding Group Co., Ltd., is a China-based pharmaceutical and medical technology company engaged in the research, development, manufacturing, and commercialization of chemical generic drugs, active pharmaceutical ingredients (APIs), innovative biopharmaceuticals, and clinical medical devices. Tracing its operational roots to 1999 and incorporated in its current structure in May 2019, the company is headquartered in Beijing, China, and operates multi-site manufacturing and R&D facilities across Beijing, Cangzhou in Hebei Province, Xuancheng in Anhui Province, and Hangzhou in Zhejiang Province. Beijing Foyou Pharma operates an integrated API-to-formulation supply chain, serving hospital networks, clinical care institutions, and retail pharmacies across domestic and international markets.
The company's core business is organized into two primary segments: Pharmaceutical Preparations and Medical Devices. The Pharmaceutical Preparations segment provides treatments across several key therapeutic categories: cardiovascular medications, including Telmisartan Tablets sold under the Shuniya brand, Telmisartan-Hydrochlorothiazide Tablets, Olmesartan Medoxomil Tablets and Orally Disintegrating Tablets, Valsartan-Amlodipine tablets, and Clopidogrel-Aspirin Tablets; endocrine and diabetes therapies, including Repaglinide Tablets sold under the Wansheng Liping brand, Epalrestat Tablets, and Saxagliptin-Metformin; chronic kidney disease therapies, including Compound Alpha-Ketoacid Tablets sold under the Keluodi brand; dermatological and topical drugs, including Fluticasone Propionate Creams, specialized glucocorticoid formulations, and functional skin barrier agents; and digestive, neuropsychiatric, respiratory, and gynecological drugs, including Dydrogesterone Tablets, Acetylcysteine Tablets, and selective psychotropic formulations. The Medical Devices segment specializes in clinical nursing, patient monitoring, and respiratory care equipment: medical micro-mesh nebulizers; disposable oxygen delivery masks and nasal cannula systems; digital urine collection systems and intelligent volume monitors; urodynamic monitoring apparatus; and disposable medical pressure transducers.
In recent developments, Beijing Foyou Pharma has advanced its strategic transformation toward innovative biomedicine by leveraging its proprietary N-ER oligonucleotide drug delivery platform to advance multiple small interfering RNA (siRNA) therapeutic candidates into Phase I clinical trials for liver-targeted and extrahepatic metabolic indications. Concurrently, the company has expanded its commercial portfolio through National Medical Products Administration (NMPA) regulatory approvals for new generic formulations, including first-to-market approvals for Olmesartan Medoxomil orally disintegrating tablets, Clopidogrel-Aspirin combination tablets, and Dydrogesterone tablets, with over 90 products having passed national consistency evaluations. Additionally, the company has broadened its institutional market coverage by securing tender awards for 23 commercial drug products under China's National Centralized Volume-Based Procurement program while expanding strategic academic-industry research collaborations for oligonucleotide synthesis and specialized drug delivery systems.